Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

IDEC-114 (IDEC).

¹Johannes Gutenberg University, Department of Dermatology, Mainz, Germany. schopf@hautlink.klink.uni-mainz.de

Current Opinion in Investigational Drugs (London, England : 2000)

|September 25, 2001

Summary

IDEC-114, a novel PRIMATIZED-anti-B7 antibody, is being evaluated for autoimmune and inflammatory diseases like psoriasis. Phase II trials are assessing its safety and efficacy in patients with moderate-to-severe psoriasis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An exploratory, prospective, open-label trial of ingenol mebutate gel 0.05% for the treatment of external anogenital warts.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017

Same author

An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2016

Same author

Ingenol mebutate gel is effective against anogenital warts - a case series in 17 patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2015

Same author

Interactions between epidermal cells and lymphocytes in psoriasis.

Immunology today·2014

Same author

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.

The British journal of dermatology·2013

Same author

Pimecrolimus (Novartis).

IDrugs : the investigational drugs journal·2005

Area of Science:

Immunology
Pharmacology

Background:

IDEC-114 is a PRIMATIZED antibody targeting the B7 antigen on antigen-presenting cells.
B7 antigen interaction with T-cells initiates immune responses, making anti-B7 antibodies potential treatments for autoimmune diseases and transplant rejection.
PRIMATIZED antibodies combine primate and human components, potentially reducing adverse reactions for chronic use.

Purpose of the Study:

To evaluate the clinical activity and safety of IDEC-114 in patients with moderate-to-severe psoriasis.
To assess the therapeutic potential of IDEC-114 for autoimmune and inflammatory conditions.

Main Methods:

A randomized, blind, placebo-controlled, multiple-dose phase II study.
Enrollment of patients with moderate-to-severe psoriasis.

Main Results:

Phase II trials are currently underway to determine the efficacy and safety of IDEC-114.
The antibody targets B7 antigens, crucial for T-cell mediated immune responses.

Conclusions:

IDEC-114 shows promise as a treatment for autoimmune and inflammatory diseases.
Further clinical trials are necessary to confirm the safety and efficacy of IDEC-114.

Related Experiment Videos